Search
Close this search box.
Register
Healthed-White-on-Blue
Search
Close this search box.
Mater-Director-of-Infectious-Diseases-Dr-Paul-Griffin

Prof Paul Griffin

Infectious Diseases Physician and Clinical Microbiologist; Director of Infectious Diseases, Mater Hospital; Lecturer, University of Queensland
An Infectious Diseases Physician and Clinical Microbiologist, Prof Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Services in 2013, and most recently, to his conjoint role as Head of the Mater Clinical Unit for the University of Queensland School of Medicine. Prof Griffin is an accomplished clinical trial investigator, having fulfilled the role of Principal Investigator in over 150 clinical trials, particularly in Infectious Diseases including 8 COVID-19 vaccines. Despite an already demanding role at the Mater, Prof Griffin continues as a member of the AMA Queensland Council 2023-2024, and as board member and scientific advisory board member of the Immunisation Coalition, with active interest in vaccine education and advocacy, becoming a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.

More from this expert

shutterstock_1850607559
Podcasts iconPodcasts

COVID antivirals in the elderly

Learn how to educate your older patients on how to stay protected from COVID-19, as well as vaccination tips, the role of antivirals in reducing severe COVID infection, managing risks for vulnerable patients, and practical prevention strategies in this latest podcast

covid and elderly
Podcasts iconPodcasts

COVID & the elderly

COVID is still very much around, and older people are still most at risk of significant morbidity. We discuss management strategies, both in the community and in facilities, that can be beneficial in mitigating this risk.

Paul-Griffin
Videos iconVideos

Protein based COVID-19 vaccine

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains the recombinant protein nanoparticle COVID-19 vaccine with a proprietary adjuvant, including the mechanism of action, efficacy, and tolerability; and provides an update on boosters, indications, and access (8 mins).

Second,Wave,Virus,Surge,Outbreak,And,Coronavirus,Pandemic,And,Covid
Podcasts iconPodcasts

Get up to speed on the new COVID wave

The new COVID wave comprising of BQ1, XBB and other variants, and what our frontline response should look like, whether a fifth booster is worth having, children's vaccination developments and an update on the antivirals

Screenshot 2022-11-22 114859_PAUL
Videos iconVideos

Understanding the advantages of cell-based influenza vaccines

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains Australia’s first and only cell-based influenza vaccine, as well as the differences between influenza vaccines and why this is important to understand in order to better inform patients of the choices available (5 mins).

Child,Have,Sore,Throat,Sick.,Diphtheria,Sufferer.,A,Condition,Marked
Podcasts iconPodcasts

Diphtheria Update

A high index of suspicion based on vaccination status, travel and exposure history will help raise a red flag- GPs are once again at the forefront of identifying, treating and ensuring that we commence the appropriate public health interventions.

mufid-majnun-cM1aU42FnRg-unsplash

What is COVAX-19, the most advanced of Australia’s remaining local COVID vaccine candidates?

By Prof Paul Griffin
Clinical Articles iconClinical Articles
pexels-anna-shvets-4167541

COVID Update – Fourth jab, Ba2 update, flurona, antivirals

Ba2, Deltacron, Omicron and other variants- the winter booster - for which patients? An update on the other vaccines and the COVID antivirals.

By Prof Paul Griffin
Podcasts iconPodcasts
pexels-iconcom-169357

Japanese encephalitis is in Australia – A practical guide

This mosquito-transmitted disease has already killed a handful of people, and is likely to become more common- an effective vaccine will soon be made widely available to those at risk.

By Prof Paul Griffin
Podcasts iconPodcasts
Anatomical,Human,Heart,Wrapped,In,Chains.,Represents,Broken,Heart,Or

COVID Update – New advice, Coronary concern, Ba5

New advice on when to vaccinate after COVID infection

By Prof Paul Griffin
Podcasts iconPodcasts
Child,Have,Sore,Throat,Sick.,Diphtheria,Sufferer.,A,Condition,Marked

Diphtheria Update

A high index of suspicion based on vaccination status, travel and exposure history will help raise a red flag- GPs are once again at the forefront of identifying, treating and ensuring that we commence the appropriate public health interventions.

By Prof Paul Griffin
Podcasts iconPodcasts
Thermometer,,Syringe,,Ampoules,,Pills,,Crumpled,Paper,Napkin,And,Yellow,Fallen

Lagevrio questions, mRNA jab misunderstandings and nasal vaccines coming

Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time. Additionally COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed

By Prof Paul Griffin
Podcasts iconPodcasts
Screenshot 2022-11-22 114859_PAUL

Understanding the advantages of cell-based influenza vaccines

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains Australia’s first and only cell-based influenza vaccine, as well as the differences between influenza vaccines and why this is important to understand in order to better inform patients of the choices available (5 mins).

By Prof Paul Griffin
Videos iconVideos
Second,Wave,Virus,Surge,Outbreak,And,Coronavirus,Pandemic,And,Covid

Get up to speed on the new COVID wave

The new COVID wave comprising of BQ1, XBB and other variants, and what our frontline response should look like, whether a fifth booster is worth having, children's vaccination developments and an update on the antivirals

By Prof Paul Griffin
Podcasts iconPodcasts
Paul-Griffin

Protein based COVID-19 vaccine

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains the recombinant protein nanoparticle COVID-19 vaccine with a proprietary adjuvant, including the mechanism of action, efficacy, and tolerability; and provides an update on boosters, indications, and access (8 mins).

By Prof Paul Griffin
Videos iconVideos
shutterstock_1688596069

COVID update – Recent statistics and recent ATAGI updates

Basic statistics, epidemiology, and important events, and new variants and subvariants

By Prof Paul Griffin
Podcasts iconPodcasts
covid and elderly

COVID & the elderly

COVID is still very much around, and older people are still most at risk of significant morbidity. We discuss management strategies, both in the community and in facilities, that can be beneficial in mitigating this risk.

By Prof Paul Griffin
Podcasts iconPodcasts
Herpes,Zoster,Vaccine,In,A,Vial,,Immunization,And,Treatment,Of

Herpes zoster immunisation update

By Prof Paul Griffin
Podcasts iconPodcasts

Education by clinicians, for clinicians

Get the app

Site

Company

Connect

Legal

Discover

Healthed

CPD platform